Inovio Biomedical Corp. (NYSEMKT:INO)

INO promises to change the way Cancer is treated, they have consistently placed its science on the table and demonstrated efficacy in its clinical trials. I did not like it when they diluted share value but it may work to the advantage of the company as it finances it growth.

their vaccine is a potential game changer on multiple levels. they maybe a buyout target from bigger pharm

Massive pipeline, undervalued

Another one I thought i had rated as I have owned for awhile. Highly speculative - interesting products and markets - followed insiders in. Be willing to lose your entire investment.

Following zz. I think. I don't remember. Underperform.

This company is tackling major diseases such as cancer, flu, and HIV. Their recent trial of the genetic vaccine for influenza yielded positive results and looks to continue in the same direction.

Inovio is another one of those annoying little microcap vaccine companies that is always promising the world but never seems to go anywhere (see Novavax, Sinovac). They report phase I data the way other biopharmas report phase III data, so one can only imagine how excited they would get about phase III data if they ever actually progressed anything to a phase III trial. I knocked myself out of score leadership contention with my last ill-fated green thumb, and now I'm giving it another shot. I wanted 0.5 but after a near miss at an upward run on some encouraging H1N1 vaccine data (phase I of course) I decided to settle for 0.6 instead. Now let's see how fast they can drop below 0.5.

The CEO is a one-man powerhouse, there are a lot of companies with a less voluminous and less interesting pipeline with ridiculous prices, I think Inovio's price is ridiculously low.

Pure speculation play. If any one of their present immunization products works out, the company will flourish and a major impact will come about for whichever disease is effected.

Inovio has several trials going on for DNA vaccines and have already shown some great success. With insiders buying at recent 52 week lows, it appears this stock may be in for a reversal with no end in sight as it gets some fuel on its way up with inevitable phase III trials. A buyout is also possible in it's future as a partnering with Merck is already in play.

The drugs in the pipeline will explode this stock if they make it to market.

I think this stock has huge potential, a slow starter recently, but I think they will come alive within 2 years.

The genetic vaccines are the future, so Dr. House series use them. The hability to create very good targeted vaccine to attack only some type of disase like AIDS, Cancer and others without damaging other tissue is a dream. Just think about that: someone you know is sick with cancer, so in the labs they extract a small sample of tissue, "program" the vaccine to attack only that type of tissue, and dispense the vaccine to the person, and the immunological system is teached to destroy the bad tissue without touching anything else. Will take some time, but when approved, this company will explode like a new born star.

flu vaccine not based on old outdated viruses...uses DNA to fight viruses naturally

Once they get FDA approval, this stock should soar. Just hope that they get FDA approval...

They are or should be a part of the H1N1 ordeal and begin a turn around in the next 2 weeks possibly a few months. Depending on the severity of the H1N1 Virus.

1)AUG 1 2009 WINE FLU RESULTS CAME IN AT 100 % DEFEATED WHEN IT WAS INJECTED INTO THE PIGS..

2) AUG 5 2009 SUPPIRISE THE COMPANY HAS A PIPE LINE OF SUCCESS AS THE NEW FOR TODAY STATES THE CANCER CLINICAL STUDIES ARE ALSO
LAMDMARK RESILTS..

ITS BIOTECH TIME UNITL THE BULL MARKET APPEARS..AND THAT WONT BE FOR 1 OR 2 YEARS
UNTIL THE ELECTRIC VEHICLE IS CHEAPER AND MORE EFFECIENT...

AND THE HEALTH CARE PROBLEM IS PUT TO BED
BY MAKING THE YOUNGER AND ADLUT GENERATION HAVE MANDITORY HEALTH INSURANCE FOR BYCICLES /SKATE BOARDS ETC..

Swine Flu Pandemic is a major issue right now, not enough supply, INO is one of the few companies that has a viable vaccine that could be used to stop H1N1. Here is a recent release from Reuters:
The U.S. Health and Human Services Department declared a public health emergency over swine flu in April, giving the Food and Drug Administration the power to allow the use of unapproved medical products including adjuvants. The health department agreed to purchase more than $415 million of the vaccine additives, while saying it may not use them if enough shots are available for U.S. residents
INO also recently sold 30 million worth of shares to institutional investors for working capital, the shares were priced at 2.70/share. Current price today is 2.09. This is an easy 25-30% gain over the next week, possibly a 100% gain if we see some continued positive news about the organization.

INO is developing vacinnes against A/H1N1 and Dengue fever.